The dual SYK/JAK inhibitor cerdulatinib demonstrates rapid tumor responses in a phase 2 study in patients with relapsed/refractory B- and T-cell non-Hodgkin lymphoma (NHL) Meeting Abstract
| Authors: | Hamlin, P. A.; Cheson, B. D.; Farber, C. M.; Feldman, T.; Fenske, T. S.; Hess, B. T.; Khatcheressian, J. L.; Miller, C. B.; Munoz, J.; Patel, M. R.; Smith, S. M.; Smith, S. D.; Stevens, D. A.; Ye, J. C.; Steele, A.; Pandey, A.; Birrell, M.; Leeds, J.; Coffey, G.; Curnutte, J. T. |
| Abstract Title: | The dual SYK/JAK inhibitor cerdulatinib demonstrates rapid tumor responses in a phase 2 study in patients with relapsed/refractory B- and T-cell non-Hodgkin lymphoma (NHL) |
| Meeting Title: | 54th Annual Meeting of the American Society of Clinical Oncology (ASCO) |
| Journal Title: | Journal of Clinical Oncology |
| Volume: | 36 |
| Issue: | 15 Suppl. |
| Meeting Dates: | 2018 Jun 1-5 |
| Meeting Location: | Chicago, IL |
| ISSN: | 0732-183X |
| Publisher: | American Society of Clinical Oncology |
| Date Published: | 2018-05-20 |
| Start Page: | 402s |
| Language: | English |
| ACCESSION: | WOS:000442916002581 |
| DOI: | 10.1200/JCO.2018.36.15_suppl.7511 |
| PROVIDER: | wos |
| Notes: | Meeting Abstract: 7511 -- Source: Wos |
